Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03461666
Other study ID # PSPC-17-01
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 5, 2018
Est. completion date July 1, 2022

Study information

Verified date March 2023
Source Pacific Institute of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study compares the efficacy of four different types (Cognitive Behavior Therapy for Insomnia (CBT-I); Focus of Attention (FOA); Combined CBT-I and FOA; and Sleep Hygiene (control group) for the treatment of insomnia. This study is a randomized, open label study, and the participants are asked to assess the benefits they get from the intervention. This study involve 6 weekly in person one-to-one sessions after screening and completion of the 1-week, 3-month, 6-month and 12-month follow-up assessment. The trained study staff will administering the treatment. The Research Department will administer the outcome measures. The review of insomnia improvement will be assessed at at end of treatment, 3 months, 6 months and 12 months follow-up.


Description:

This study compares the efficacy of four different types (Cognitive Behavior Therapy for Insomnia (CBT-I), Focus of Attention (FOA), Combined CBT-I and FOA and Sleep Hygiene) of therapies approaches for the treatment of insomnia. This study is a randomized, open label study, the participants are asked to review the benefits they get from the intervention. This study involve 6 weekly sessions after screening and completion of the end of treatment, 3-month, 6-month and 12-month follow-up assessment. The trained study staff will administer study scales during therapy session. The subjective review of insomnia improvement will be assessed at end of treatment, 3 months, 6 months and 12 months follow-up assessment. Subjects are adult who meet, DSM-5 the diagnostic criteria for primary Insomnia. Inclusion/Exclusion criteria to be assessed at Screening (Visit 1) and Visit 2. For those found eligible who complete the study, participation will include Screening (Visit 1), 6 weekly sessions after screening, and completion of the post-treatment and 6-month followup assessment. Once subject sign the consent form, subject will be asked inclusion and exclusion criteria and will be given details about the study as per protocol. Those eligible will be randomly assigned to one of four behavioral treatment approaches. The participant will have six weekly one hour in person sessions in which the assigned treatment will be administered. The participant will be assessed at the end of treatment and again at 6 month followup.


Recruitment information / eligibility

Status Terminated
Enrollment 160
Est. completion date July 1, 2022
Est. primary completion date November 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 72 Years
Eligibility Inclusion Criteria: - Male and female outpatients who are 18 or older to 72 years. Insomnia Severity Index > or = 10 - Meet diagnostic criteria for Insomnia Disorder per DSM-5 Willing and able to sign Informed consent form Not planning on moving away from the area for the subsequent 12 weeks. Exclusion Criteria: - Participants who answer "yes" to any of the following will be excluded: - Females who are lactating or who are pregnant - Night shift workers, and individuals who nap 3 or more times per week over the preceding month - Consumption of caffeine beverages (i.e. tea, coffee, or cola) comprising usually more than 5 cups or glasses per day - Participation in another trial for insomnia - Persons unable to complete the study questionnaires and psychological tests - Persons who are unable to participate for the entire duration of the study, or in the opinion of the investigators, are likely to be non-compliant with the obligations inherent in the trial participation - Persons self-describing with severe anxiety or severe depression (BDI score of 29 or higher) or severe anxiety (BAI score of 36 or higher). - Persons with a history of epilepsy, seizures, or dementia - Any significant, severe or unstable, acute or chronically progressive medical or surgical condition - Serious head injury or stroke within the past year - Current alcohol or substance abuse/dependence (must have >90 days of sobriety) - Presence of other neurological disorders (e.g., multiple sclerosis, Parkinson's Disease) - Presence of an untreated or unstable medical or psychiatric comorbid condition (e.g., major depressive disorder or psychotic disorder requiring admission within the last two years). People using psychotropic medication, hypnotic or sedative medications may be included if they are on a stable dosage for the last 2 months prior to the study, if the dose remains stable throughout the study, and if the medication is judged to not interfere with the study outcomes. - Currently on medications known to produce insomnia (e.g., stimulants) - Sleep apnea (AHI >15) or previous diagnosis of sleep apnea. Study participants who use a continuous positive airway pressure (CPAP) device for sleep apnea will be eligible for participation if they are below the apnea/hypopnea cutoff while using CPAP and agree to use the device during study participation.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Behavior Therapy-Insomnia
Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
Focus of Attention
Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
Combined-CBT-I and FOA Group
Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
Sleep Hygiene
Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Locations

Country Name City State
United States Puget Sound Psychiatric Center Bothell Washington
United States Puget Sound Psychiatry Center Bothell Washington

Sponsors (1)

Lead Sponsor Collaborator
Pacific Institute of Medical Sciences

Country where clinical trial is conducted

United States, 

References & Publications (2)

Becher AK, Hohne M, Axmacher N, Chaieb L, Elger CE, Fell J. Intracranial electroencephalography power and phase synchronization changes during monaural and binaural beat stimulation. Eur J Neurosci. 2015 Jan;41(2):254-63. doi: 10.1111/ejn.12760. Epub 2014 — View Citation

Cahn BR, Polich J. Meditation states and traits: EEG, ERP, and neuroimaging studies. Psychol Bull. 2006 Mar;132(2):180-211. doi: 10.1037/0033-2909.132.2.180. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Self Report Sleep Measures SRSM: assess overall quantity of sleep satisfaction on the Self Report Sleep Measures. through study completion, an average of 1 year
Secondary Insomnia Severity Index ISI: assess the severity of insomnia. through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT02243501 - Better Nights, Better Days for Typically Developing Children N/A
Completed NCT01636791 - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Phase 3
Completed NCT00770510 - A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126) Phase 2/Phase 3
Completed NCT00520832 - A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys Phase 2
Recruiting NCT00415714 - Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia N/A
Terminated NCT00420810 - Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED) Phase 3
Completed NCT00178048 - Paroxetine in the Treatment of Chronic Primary Insomnia Phase 4
Completed NCT00816673 - Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs Phase 2
Completed NCT01957111 - Metabolomics of Insomnia-Related Hyperarousal N/A
Completed NCT01960452 - A High Density EEG Comparison of Sleep Patterns in Insomnia N/A
Completed NCT01181232 - A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients Phase 4
Completed NCT00784875 - An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia Phase 2
Completed NCT00551148 - A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia Phase 2
Completed NCT00397189 - Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients Phase 3
Completed NCT00352144 - 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia Phase 3
Completed NCT02290405 - Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
Completed NCT03314441 - Effects of Regular Practice of Yoga on Subjective and Objective Sleep Quality in Primary Insomnia N/A
Completed NCT00792298 - Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006) Phase 2
Completed NCT01021852 - Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011) Phase 2
Completed NCT01719315 - Neurophysiologic Correlates of Hypersomnia